Project Grant HT94252410773
Award Date
10/1/24
Completion Date
9/30/26
Dollars Obligated
$400K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This federal Project Grant award, valued at $1,100,747.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to engineer antibody-drug conjugates that can coordinate the innate and adaptive immune systems for curative responses. The primary awardee is the Regents of the University of Michigan, a prominent U.S. state government-owned educational institution with extensive expertise in federal research and...
The Defense Health Agency awarded a $159,892 Project Grant to the University of Illinois under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into "Metabolic Vulnerabilities Associated to G12C Inhibitor Resistance" from January 1, 2022 through December 31, 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
This federal Project Grant award of $1,848,000.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports advanced biomedical research focused on transforming healthcare for military service members and the broader public. The grant, awarded to the Regents of the University of Minnesota, aims to conduct therapeutic research targeting aberrant mRNA polyadenylation in lethal prostate cancer. This research, to be performed from July 1,...
The federal Project Grant award of $312,610.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award is to support research on the "ROLE OF FUNCTIONAL FACTORS IN AR REPROGRAMMING AND PROGRESSION OF PROSTATE CANCER". The award was made to Weill Medical College of Cornell University, a prominent academic medical institution, on September 30, 2024, with a performance period ending on September 29,...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
This Project Grant award, valued at $592,500.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports the development of a "Mutant DNA-Activated Killing System for Precision Breast Cancer Therapy" at the University of California, San Diego (UC San Diego). The research aims to advance innovative biomedical solutions for military service members and the broader public. UC San Diego, a leading...
The University of Maryland, Baltimore (UMB) was awarded a $587,271 Project Grant from the Defense Health Agency, under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), to conduct research on "DUAL INHIBITION OF PARP AND IL-6 AS A NOVEL THERAPEUTIC APPROACH FOR BRCA-MUTATED TRIPLE-NEGATIVE BREAST CANCER." This research project will occur from July 1, 2024 to June 30, 2027. The Military Medical Research and Development program supports a...
The Defense Health Agency awarded a $1,453,500.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, commencing on June 20, 2023, will support UCSF's research to profile and eliminate tumor subclones resistant to radioligand therapy. Through this project, UCSF aims to transform health care for Service Members and the American public by developing innovative and...
The U.S. Defense Health Agency awarded a $592,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the University of California, San Diego (UCSD). The grant supports the development of a "Mutant DNA-Activated Killing System for Precision Breast Cancer Therapy" over a 3-year performance period from February 2025 to January 2028. This advanced biomedical research project aims to transform healthcare for military service members and the broader...